European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338 virus - immunostimulants, antineoplastic and immunomodulating agents, immunostimulants, - cats - immunotherapy to be used in association with surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, to reduce the risk of relapse and increase the time to relapse (local recurrence or metastasis).

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - feline leukemia of felv recombinant canarypox virus vaccine (vcp97) - suspension for injection (sc) - 1 dose of 1ml or 0.5 ml contains felv recombinant canarypoxvirus (vcp97-10˄7.2ccid50

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - feline leukaemia virus recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.onset of immunity has been demonstrated 2 weeks after primary vaccination course.the duration of immunity is one year after the last vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim vetmedica gmbh - feline interleukin-2 recombinant canarypox virus - lyophilisate for suspension for injection - immunomodulator - cats

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - cats - active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity after primary vaccination: 1 year.duration of immunity after revaccination: 3 years.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline calicivirus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; thiomersal - parenteral liquid/solution/suspension - feline calicivirus - inactivated vaccine-viral active 0.0 p; feline panleucopenia virus - inactivated vaccine-viral active 0.0 p; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - cat | cat - queen | cat - tom | kitten - feline calicivirus | feline enteritis | feline rhinotracheitis | calicivirus (feline) | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 ml; feline panleucopenia virus - inactivated vaccine-viral active 0.0 ml; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 ml; amphotericin antibiotic other 0.0 ml; neomycin antibiotic other 0.0 ml; polymyxin b antibiotic other 0.0 ml; thiomersal mercury other 0.0 ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline enteritis | feline rhinotracheitis | calicivirus (feline) | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline calicivirus - inactivated; feline leukaemia virus - inactivated; feline chlamydia psittaci - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 u; feline leukaemia virus - inactivated vaccine-viral active 0.0 u; feline chlamydia psittaci - inactivated vaccine-viral active 0.0 u; feline panleucopenia virus - inactivated vaccine-viral active 0.0 u; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 u - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline chlamydia psittaci | feline enteritis | feline leukaemia virus | feline rhinotracheitis | calicivirus (feline) | disease caused by | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)